News articles about Stemline Therapeutics (NASDAQ:STML) have trended positive on Saturday, AlphaOne reports. AlphaOne, a service of Accern, ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stemline Therapeutics earned a news sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also assigned headlines about the biopharmaceutical company an impact score of 100 out of 100, indicating that recent news coverage is extremely likely to have an effect on the stock’s share price in the near term.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Shares of Stemline Therapeutics (STML) opened at 8.30 on Friday. The firm’s 50-day moving average price is $8.08 and its 200 day moving average price is $9.28. Stemline Therapeutics has a one year low of $5.50 and a one year high of $14.60. The firm’s market cap is $194.02 million.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.22. The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.30 million. Stemline Therapeutics had a negative net margin of 3,864.20% and a negative return on equity of 60.51%. Analysts predict that Stemline Therapeutics will post ($2.27) EPS for the current year.

Several equities analysts recently weighed in on STML shares. Wedbush raised their target price on shares of Stemline Therapeutics from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Cowen and Company reissued a “buy” rating on shares of Stemline Therapeutics in a research note on Thursday, March 23rd. Ladenburg Thalmann Financial Services set a $41.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Monday, March 20th. HC Wainwright reissued a “buy” rating and issued a $34.00 target price on shares of Stemline Therapeutics in a research note on Tuesday, March 28th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $16.00 target price on shares of Stemline Therapeutics in a research note on Thursday, May 25th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Stemline Therapeutics has an average rating of “Buy” and an average target price of $29.17.

COPYRIGHT VIOLATION WARNING: This piece was reported by Financial Market News and is the property of of Financial Market News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with's FREE daily email newsletter.